Sol-Gel Technologies Ltd.

As of September 4, 2025, Sol-Gel Technologies Ltd. shows a bullish trend with strong momentum indicators, despite a bearish monthly RSI and mildly bearish weekly OBV, while significantly outperforming the S&P 500 year-to-date and over the past year.

As of March 10, 2023, Sol-Gel Technologies Ltd. is considered overvalued and has shifted from a fair to a risky valuation grade due to poor financial metrics, including negative returns and a high EV to EBITDA ratio compared to its peers.

As of March 10, 2023, Sol-Gel Technologies Ltd. is considered overvalued and risky due to poor financial health, indicated by a Price to Book Value of 1.00, an EV to EBIT of -0.26, and a P/E ratio of -1.4957, alongside significant negative returns compared to the S&P 500.

As of June 17, 2025, Sol-Gel Technologies Ltd. shows a bullish trend with moderate strength, supported by positive indicators like a bullish MACD and moving averages, though caution is advised due to mildly bearish signals from the monthly Bollinger Bands.

As of March 2022, the management team of Sol-Gel Technologies Ltd. includes Chairman Mr. Moshe Arkin, CEO Dr. Alon Seri-Levy, Directors Mr. Itai Arkin, Ms. Hani Lerman, and independent Directors Dr. Shmuel Ben Zvi, Mr. Jerrold Gattegno, and Mr. Ran Gottfried. This diverse team oversees the company's governance and strategic direction.

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing topical drug products for skin diseases. As of March 2025, it has a market cap of $19.51 million, with net sales of $1 million and a net loss of $9 million.

As of Jun 18, Sol-Gel Technologies Ltd. has a market capitalization of 19.51 million, with net sales of 12.10 million and a net profit of -13.05 million over the latest four quarters. Shareholder's funds are 28.85 million, and total assets are 35.85 million.